BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 18288988)

  • 1. Detection and specific targeting of hypoxic regions within solid tumors: current preclinical and clinical strategies.
    Bache M; Kappler M; Said HM; Staab A; Vordermark D
    Curr Med Chem; 2008; 15(4):322-38. PubMed ID: 18288988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous markers of tumor hypoxia predictors of clinical radiation resistance?
    Vordermark D; Brown JM
    Strahlenther Onkol; 2003 Dec; 179(12):801-11. PubMed ID: 14652668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential risk assessments from five hypoxia specific assays: The basis for biologically adapted individualized radiotherapy in advanced head and neck cancer patients.
    Nordsmark M; Eriksen JG; Gebski V; Alsner J; Horsman MR; Overgaard J
    Radiother Oncol; 2007 Jun; 83(3):389-97. PubMed ID: 17499868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of osteopontin in advanced head-and-neck cancer: prognostic role and correlation with oxygen electrode measurements, hypoxia-inducible-factor-1alpha-related markers, and hemoglobin levels.
    Bache M; Reddemann R; Said HM; Holzhausen HJ; Taubert H; Becker A; Kuhnt T; Hänsgen G; Dunst J; Vordermark D
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1481-7. PubMed ID: 17056190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypoxic sensitizer and cytotoxin for head and neck cancer.
    Lee DJ; Moini M; Giuliano J; Westra WH
    Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxia as a Biomarker and for Personalized Radiation Oncology.
    Vordermark D; Horsman MR
    Recent Results Cancer Res; 2016; 198():123-42. PubMed ID: 27318684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors.
    Troost EG; Laverman P; Kaanders JH; Philippens M; Lok J; Oyen WJ; van der Kogel AJ; Boerman OC; Bussink J
    Radiother Oncol; 2006 Aug; 80(2):157-64. PubMed ID: 16905213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy.
    Stieb S; Eleftheriou A; Warnock G; Guckenberger M; Riesterer O
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2201-2217. PubMed ID: 30128659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway.
    De Ridder M; Van Esch G; Engels B; Verovski V; Storme G
    Bull Cancer; 2008 Mar; 95(3):282-91. PubMed ID: 18390408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
    Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
    J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers.
    Bussink J; Kaanders JH; van der Kogel AJ
    Radiother Oncol; 2003 Apr; 67(1):3-15. PubMed ID: 12758235
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Qian Y; Von Eyben R; Liu Y; Chin FT; Miao Z; Apte S; Carter JN; Binkley MS; Pollom EL; Harris JP; Prionas ND; Kissel M; Simmons A; Diehn M; Shultz DB; Brown JM; Maxim PG; Koong AC; Graves EE; Loo BW
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1183-1192. PubMed ID: 29859786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia in head and neck cancer: how much, how important?
    Janssen HL; Haustermans KM; Balm AJ; Begg AC
    Head Neck; 2005 Jul; 27(7):622-38. PubMed ID: 15952198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of nicotinamide and carbogen on oxygenation in human tumor xenografts measured with luminescense based fiber-optic probes.
    Bussink J; Kaanders JH; Strik AM; van der Kogel AJ
    Radiother Oncol; 2000 Oct; 57(1):21-30. PubMed ID: 11033185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD; Taylor A; Osorio L; Ochakovskaya R; Raleigh JA; Papadopoulou M; Bloomer WD; Goldenberg DM
    Int J Cancer; 2001 Nov; 94(4):564-71. PubMed ID: 11745445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic targeting of HIF-dependent glycolysis reduces lactate, increases oxygen consumption and enhances response to high-dose single-fraction radiotherapy in hypoxic solid tumors.
    Leung E; Cairns RA; Chaudary N; Vellanki RN; Kalliomaki T; Moriyama EH; Mujcic H; Wilson BC; Wouters BG; Hill R; Milosevic M
    BMC Cancer; 2017 Jun; 17(1):418. PubMed ID: 28619042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode.
    Mortensen LS; Buus S; Nordsmark M; Bentzen L; Munk OL; Keiding S; Overgaard J
    Acta Oncol; 2010 Oct; 49(7):934-40. PubMed ID: 20831480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer.
    Kaanders JH; Wijffels KI; Marres HA; Ljungkvist AS; Pop LA; van den Hoogen FJ; de Wilde PC; Bussink J; Raleigh JA; van der Kogel AJ
    Cancer Res; 2002 Dec; 62(23):7066-74. PubMed ID: 12460928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical radiosensitizers for use in radiotherapy.
    Wardman P
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):397-417. PubMed ID: 17478086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved recurrence-free survival with ARCON for anemic patients with laryngeal cancer.
    Janssens GO; Rademakers SE; Terhaard CH; Doornaert PA; Bijl HP; van den Ende P; Chin A; Takes RP; de Bree R; Hoogsteen IJ; Bussink J; Span PN; Kaanders JH
    Clin Cancer Res; 2014 Mar; 20(5):1345-54. PubMed ID: 24452791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.